249 related articles for article (PubMed ID: 32176739)
1. STUB1 is targeted by the SUMO-interacting motif of EBNA1 to maintain Epstein-Barr Virus latency.
Wang Y; Du S; Zhu C; Wang C; Yu N; Lin Z; Gan J; Guo Y; Huang X; He Y; Robertson E; Qu D; Wei F; Cai Q
PLoS Pathog; 2020 Mar; 16(3):e1008447. PubMed ID: 32176739
[TBL] [Abstract][Full Text] [Related]
2. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
3. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
4. A unique SUMO-2-interacting motif within LANA is essential for KSHV latency.
Cai Q; Cai S; Zhu C; Verma SC; Choi JY; Robertson ES
PLoS Pathog; 2013; 9(11):e1003750. PubMed ID: 24278015
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.
Mansouri S; Pan Q; Blencowe BJ; Claycomb JM; Frappier L
J Virol; 2014 Oct; 88(19):11166-77. PubMed ID: 25031339
[TBL] [Abstract][Full Text] [Related]
6. Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.
Deakyne JS; Malecka KA; Messick TE; Lieberman PM
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701406
[TBL] [Abstract][Full Text] [Related]
7. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
9. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
10. IFI16 Partners with KAP1 to Maintain Epstein-Barr Virus Latency.
Xu H; Li X; Rousseau BA; Akinyemi IA; Frey TR; Zhou K; Droske LE; Mitchell JA; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2022 Sep; 96(17):e0102822. PubMed ID: 35969079
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of EBNA1-host protein interactions in latent and lytic Epstein-Barr virus infections.
Malik-Soni N; Frappier L
J Virol; 2012 Jun; 86(12):6999-7002. PubMed ID: 22496234
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies.
Sivachandran N; Sarkari F; Frappier L
PLoS Pathog; 2008 Oct; 4(10):e1000170. PubMed ID: 18833293
[TBL] [Abstract][Full Text] [Related]
13. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.
Yin Q; Flemington EK
Virology; 2006 Mar; 346(2):385-93. PubMed ID: 16343579
[TBL] [Abstract][Full Text] [Related]
14. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
15. EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication.
Sarkari F; Sanchez-Alcaraz T; Wang S; Holowaty MN; Sheng Y; Frappier L
PLoS Pathog; 2009 Oct; 5(10):e1000624. PubMed ID: 19834552
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.
Lee EK; Kim SY; Noh KW; Joo EH; Zhao B; Kieff E; Kang MS
Antiviral Res; 2014 Apr; 104():73-83. PubMed ID: 24486954
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.
Messick TE; Smith GR; Soldan SS; McDonnell ME; Deakyne JS; Malecka KA; Tolvinski L; van den Heuvel APJ; Gu BW; Cassel JA; Tran DH; Wassermann BR; Zhang Y; Velvadapu V; Zartler ER; Busson P; Reitz AB; Lieberman PM
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842315
[TBL] [Abstract][Full Text] [Related]
18. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
[TBL] [Abstract][Full Text] [Related]
19. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.
Sivachandran N; Wang X; Frappier L
J Virol; 2012 Jun; 86(11):6146-58. PubMed ID: 22491455
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
